Last reviewed · How we verify
FLURPIRIDAZ F 18
At a glance
| Generic name | FLURPIRIDAZ F 18 |
|---|---|
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2024 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. (PHASE3)
- A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress (PHASE1)
- A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158 (PHASE1)
- Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158 (PHASE2)
- Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI (PHASE3)
- A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLURPIRIDAZ F 18 CI brief — competitive landscape report
- FLURPIRIDAZ F 18 updates RSS · CI watch RSS